Cenobamate (CNB) has shown efficacy in reducing seizures in drug-resistant epilepsy (DRE) in clinical trials. We conducted a retrospective study at the Centre hospitalier de l’Université de Montréal epilepsy clinic to assess CNB’s real-world efficacy and safety. Among 109 patients, follow-up data were available for 68 at 3 months, 53 at 6 months and 54 at 12 months. Median seizure frequency reduction was 50.0%, 57.3% and 73.3%, respectively. Seizure freedom at 12 months was 25.9%. CNB was discontinued in 8.3% of individuals due to adverse events (non-serious) or treatment inefficacy. Our findings support CNB’s effectiveness in a DRE population.
